Amicus Therapeutics — Technical Presentation (February 2021)
27 slides from Amicus Therapeutics's technical presentation, Feb 11, 2021
Slide 1: AT-GAA (ATB200/AT2221) Phase 3 PROPEL Topline Results
AT-GAA (ATB200/AT2221) Phase 3 PROPEL Topline Results February 11, 2021
Slide 2: Forward-Looking Statements
Phase 3 PROPEL Topline Results 2 Forward-Looking Statements This presentation contains "forward-looking statements" within themeaningof the PrivateSecurities Litigation Reform Act of 1995, including statements relating to top-line data from a global Phase 3 study to investigate AT-GAA for the treatm
Slide 3: Introduction: Our Passion for Making a Difference Unites Us
Introduction: Phase 3 PROPEL Topline Results 3 Our Passion for Making a Difference Unites Us Per Ardua Ad Astra
Slide 4: Executive Summary
Phase 3 PROPEL Topline Results 4 Executive Summary » Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021 Patients switching to AT-GAA from the approved ERT, alglucosidase alfa, walked +16.9 meters farther than t
Slide 5: Pompe Disease Overview
Phase 3 PROPEL Topline Results 5 Pompe Disease Overview 5,000 – 10,000+ patients diagnosed WW1; newborn screening suggests underdiagnosis Respiratory and cardiac failure are leading causes of morbidity and mortality Age of onset ranges from infancy to adulthood Patients on currently approved ERT dec
Slide 6: AT-GAA: ATB200 (cipaglucosidase alfa) and AT2221 (miglustat)
Phase 3 PROPEL Topline Results 6 AT-GAA: ATB200 (cipaglucosidase alfa) and AT2221 (miglustat) ATB200 is a novel rhGAA being developed as a next-generation enzyme replacement therapy (ERT) for the treatment of Pompe disease, used in conjunction with AT2221, an iminosugar that stabilizes and enhances
Slide 7: PROPEL (ATB200-03): Study Design
Phase 3 PROPEL Topline Results 7 PROPEL (ATB200-03): Study Design 52-Week Primary Treatment Period (Double-Blind) Enrollment AT-GAA (n=85) n=123 20 mg/kg ATB200 IV + 260 mg of AT2221 qow ERT Experienced & ERT Naïve Alglucosidase alfa (n=38) ClinicalTrials.gov Identifier: NCT04138277 62 WW Clinical S
Slide 8: Study Objectives and Statistical Methods
Phase 3 PROPEL Topline Results 8 Study Objectives and Statistical Methods Primary and Secondary Objectives Statistical Methods • To assess the efficacy of AT-GAA compared with alglucosidase alfa/placebo on: Primary endpoint of 6MWD analyzed using MMRM on ITT observed cases All key secondary endpoint
Slide 9: Study Endpoints
Phase 3 PROPEL Topline Results 9 Study Endpoints Other Key Secondary Endpoints Primary Endpoint Change from baseline to Week 52 in 6 Minute Walk Distance (6MWD) • Change from baseline to Week 52 in the manual muscle test (MMT) score for lower extremities Change from baseline to Week 52 in the PROMIS
Slide 10: Patient Disposition
Phase 3 PROPEL Topline Results 10 Patient Disposition Patients Randomized N=123 & Dosed AA N=85 enced N=65 ve N=20 Alglucosidase Alfa N=38 ERT Experienced N=30 ERT Na Discontinued N=5 (IAR=2) (Other*=3 ) Discontinued N=1 (AE^=1) ITT: Primary Analysis N=85 ITT: Primary Analysis N=38 ATB200-07 OLE AT-
Slide 11: Baseline Demographics
Phase 3 PROPEL Topline Results 11 Baseline Demographics AT-GAA n=85 Alglucosidase alfaTotal n=38n=123 Age (years) Mean (SD) 47.6 (13.3) 45.1 (13.3)46.8 (13.3) Median (Min, Max) 48.0 (19, 74) 46.0 (22, 66)47.0 (19, 74) Gender, n (%) Male 36 (42.4) 20 (52.6)56 (45.5) Female 49 (57.6) 18 (47.4)67 (54.5
Slide 12: Baseline Characteristics
Phase 3 PROPEL Topline Results 12 Baseline Characteristics 6MWD=6-minute walk distance; FVC=forced vital capacity Results exclude one clinically implausible patient who used an investigational anabolic steroid ostarine (selective androgen receptor modulator) just prior to study start. AT-GAA n=85 Al
Slide 13: 6MWD and FVC Results: Overall Population (n=122)
Phase 3 PROPEL Topline Results 13 6MWD and FVC Results: Overall Population (n=122) 6MWD (m) FVC (% predicted) NOTES: Baseline is Mean (STDEV); CFBL is Mean LOCF (SE); P-values are nominal 2-sided; FVC data normally distributed and p–values are from ANCOVA. Results exclude one clinically implausible
Slide 14: 6MWD and FVC Results: ERT Experienced Population (n=95)
Phase 3 PROPEL Topline Results 14 6MWD and FVC Results: ERT Experienced Population (n=95) 6MWD (m) FVC (% predicted) NOTE: Baseline is Mean (STDEV); CFBL is Mean LOCF (SE); P-values are nominal 2-sided; FVC data normally distributed and p–values are from ANCOVA 6MWD data not normally distributed and
Slide 15: 6MWD and FVC Plots: ERT Experienced Population (n=95)
Phase 3 PROPEL Topline Results 15 6MWD and FVC Plots: ERT Experienced Population (n=95) 6MWD (m): Change from baseline (n=65, n=30) FVC (% predicted): Change from baseline (n=65, n=30) 2.0 1.5 30 1.0 25 0.5 0.0 20 -0.5 -1.0 -1.5 15 10 -2.0 -2.5 5 -3.0 -3.5 -4.0 0 -2 -4 -6 -8 -4.5 -5.0 Bas eline Week
Slide 16: 6MWD and FVC Results: ERT Naive Population (n=27)
Phase 3 PROPEL Topline Results 16 6MWD and FVC Results: ERT Naive Population (n=27) 6MWD (m) FVC (% predicted) NOTES: Baseline is Mean (STDEV); CFBL is Mean LOCF (SE); P-values are nominal 2-sided; FVC data normally distributed and p–values are from ANCOVA. Results exclude one clinically implausible
Slide 17: Key Secondary: Lower MMT
Phase 3 PROPEL Topline Results 17 Key Secondary: Lower MMT All Patients & ERT Experienced Patients Overall Population ERT Experienced Population 2.5 2.5 ↑ Improvement 2.0 2.0 1.5 1.5 1.0 1.0 0.5 0.5 0.0 0.0 Baseline Week 12 Week 26 Visit Week 38 Week 52 LOCF Bas eline Week 12 Week 26 Visit Week 38 W
Slide 18: Key Secondary: GSGC (Gait, Stairs, Gowers, Chair)
Phase 3 PROPEL Topline Results 18 Key Secondary: GSGC (Gait, Stairs, Gowers, Chair) All Patients & ERT Experienced Patients ERT Experienced Population Overall Population 1.5 1.5 1.0 1.0 0.5 0.5 0.0 0.0 -0.5 -0.5 -1.0 -1.0 -1.5 -1.5 Bas eline Week 12 Week 26 Visit Week 38 Week 52 LOCF Baseline Week 1
Slide 19: Key Secondary: PROMIS Physical Function
Phase 3 PROPEL Topline Results 19 Key Secondary: PROMIS Physical Function All Patients & ERT Experienced Patients Overall Population ERT Experienced Population 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 -1.5 -2.0 -2.5 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5 -1.0 -1.5 -2.0 -2.5 -3.0 -3.5 -4.0 ↑ Impro
Slide 20: Key Secondary: PROMIS Fatigue
Phase 3 PROPEL Topline Results 20 Key Secondary: PROMIS Fatigue All Patients & ERT Experienced Patients Overall Population ERT Experienced Population 0.0 1.0 0.5 -0.5 0.0 -1.0 -0.5 -1.0 -1.5 -1.5 -2.0 -2.0 -2.5 -2.5 -3.0 -3.0 Bas eline Week 12 Week 26 Visit Week 38 Week 52 LOCF Baseline Week 12 Week
Slide 21: Biomarker: Creatine Kinase (CK)
Phase 3 PROPEL Topline Results 21 Biomarker: Creatine Kinase (CK) All Patients & ERT Experienced Patients Overall Population ERT Experienced Population 30 30 20 20 10 10 0 0 -10 -10 -20 -20 -30 -30 Bas eline Week 12 Week 26 Visit Week 38 Week 52 LOCF Baseline Week 12 Week 26 Visit Week 38 Week 52 LO
Slide 22: Biomarker: Urinary Hex4
Phase 3 PROPEL Topline Results 22 Biomarker: Urinary Hex4 All Patients & ERT Experienced Patients Overall Population ERT Experienced Population 30 30 20 20 18.4% 10 10 0 0 -10 -10 -20 -20 -30 -31.5% -30 -40 -40 Baseline Week 12 Week 26 Visit Week 38 Week 52 LOCF Bas eline Week 12 Week 26 Visit Week
Slide 23: Primary, Key Secondary and Biomarker Endpoint Heat Map
Phase 3 PROPEL Topline Results 23 Primary, Key Secondary and Biomarker Endpoint Heat Map All Patients & ERT Experienced Patients Overall Population ERT Experienced Population Note: * Nominal P-value <0.05; based on LOCF means Alglucosidase alfa AT-GAA Motor Function 6MWD* GSGC* Pulmonary Function FV
Slide 24: Safety Summary
Phase 3 PROPEL Topline Results 24 Safety Summary • • • TEAEs leading to withdrawal in the AT-GAA arm were two IARs, one of which was a serious AE TEAEs leading to withdrawal in the alglucosidase arm was due to stroke (unrelated) Overall safety profile of AT-GAA is similar to alglucosidase alfa AT-GA
Slide 25: AT-GAA: Next Steps
Phase 3 PROPEL Topline Results 25 AT-GAA: Next Steps • • Rolling BLA submission expected to complete in Q2 Other key regulatory submissions for approval throughout 2021 including MAA Europe Potential for early approval under EAMS framework with Priority Innovative Medicines Designation in UK 150+ pa
Slide 26: Acknowledgments
Phase 3 PROPEL Topline Results 26 Acknowledgments • Amicus thank the patients, their families, and Pompe disease patient organizations for their participation in the PROPEL study sponsored by Amicus Therapeutics Amicus would also like to thank the investigators, and site staff for their support and
Slide 27: Thank You
ThankYou
Amicus Therapeutics — Technical Presentation (February 2021) on 6ix